Illumina Files Patent Infringement Suit in the United Kingdom Against Premaitha Health plc for Infringement of NIPT Patents
March 16 2015 - 4:05AM
Business Wire
Illumina, Inc. (NASDAQ:ILMN) today announced that it and its
wholly-owned subsidiary, Verinata Health Inc., (together
“Illumina”) have filed a patent infringement suit against Premaitha
Health plc in the High Court of Justice, Chancery Division, Patents
Court in the United Kingdom. Illumina is seeking all available
remedies, including damages and injunctive relief.
The patents asserted are European Patent (UK) 0 994 963 B2 and
European Patent (UK) 1 981 995 B1, which are exclusively licensed
to Illumina from Sequenom, Inc. and The Board of Trustees of Leland
Stanford Junior University, respectively. Stanford is joined in the
suit as a necessary party because it is the registered owner of the
European Patent (UK) 1 981 995 B1. The patents are directed to
using cell-free fetal DNA for non-invasive prenatal testing (NIPT).
The suit accuses Premaitha’s IONA® Test of infringement, including
its use of next-generation sequencing to analyze cell-free fetal
DNA from a sample of maternal blood.
“Illumina filed this suit to actively defend its intellectual
property rights. We will also continue to monitor the NIPT field
and file patent suits where appropriate when our patents are
infringed,” said Charles Dadswell, Senior Vice President and
General Counsel for Illumina.
About Illumina
Illumina is transforming human health as the global leader in
sequencing and array-based technologies. The company serves
customers in a broad range of markets, enabling the adoption of
genomic solutions in research and clinical settings. To learn
how Illumina is unlocking the power of the genome, visit
www.illumina.com and follow @illumina.
Illumina, Inc.Investors:Rebecca
Chambers858-255-5243rchambers@illumina.comorMedia:Jennifer
Temple858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2024 to May 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From May 2023 to May 2024